Situation: A 72-year-old man with prostate cancer that has spread to the spine and pelvis is admitted to the oncology ward for pain control. The oncologist starts leuprolide and prescribes bicalutamide for the first few weeks. What is the purpose of the bicalutamide?

Leuprolide is a gonadotropin-releasing hormone agonist that eventually suppresses testosterone but first causes a surge. This surge can cause a tumor flare, worsening bone pain or spinal and urinary obstruction. An antiandrogen such as bicalutamide blocks androgen receptors during the first weeks to prevent the flare.

Purpose of bicalutamide at leuprolide initiation

Leuprolide belongs to the GnRH agonist class. When it first occupies the GnRH receptor on pituitary gonadotropes, it does not immediately suppress the axis. Instead, it produces a transient but real stimulatory phase in which luteinizing hormone release rises, and serum testosterone climbs above baseline for roughly the first 1–2 weeks before receptor downregulation finally suppresses testosterone to castrate levels ^[1][3]. In a patient whose prostate cancer has already metastasized to the spine and pelvis, that early testosterone elevation can drive a tumor flare: the androgen-sensitive cancer cells are briefly stimulated, which may worsen bone pain, increase spinal cord compression risk, or precipitate urinary obstruction.

Bicalutamide is a non-steroidal antiandrogen. It does not lower testosterone production; rather, it competes with testosterone and dihydrotestosterone at the androgen receptor on prostate cancer cells. When started before or at the same time as leuprolide and continued for the first few weeks, bicalutamide occupies those receptors so that the surge of circulating testosterone has no functional target. This is the rationale for combined androgen blockade during the initial phase of GnRH agonist therapy: the antiandrogen blocks the clinical consequences of the testosterone flare while the agonist gradually achieves receptor downregulation and testosterone suppression ^[1][2].

The other options do not match the mechanism. Hot flashes are a later consequence of androgen deprivation, not an early surge effect, and bicalutamide does not treat them. Prostate volume reduction before radiation is a separate goal of androgen deprivation and is not the reason for short-term antiandrogen coverage at leuprolide initiation. Bone loss is a long-term complication of sustained castrate testosterone levels; bicalutamide has no role in preventing it.

Watch out! The timing matters. The flare risk is highest during the first 2–4 weeks after the first leuprolide injection, so antiandrogen coverage is specifically a short-term, early intervention. Once testosterone is suppressed, the antiandrogen is generally no longer needed for flare prevention.

Key point! Leuprolide first stimulates, then suppresses. Bicalutamide blocks the receptor so the stimulation cannot act on the tumor. This is why a patient with spinal metastases needs antiandrogen coverage before the testosterone surge can worsen cord compression or pain ^[3].